ArticleFrontiers in molecular neuroscience2024
Risk factors for poor prognosis in patients with zoster-associated neuralgia who underwent interventional pain management.
Article in Frontiers in molecular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Construction and validation of a prediction system for postherpetic neuralgia: based on meta-analysis.Scientific reports · 2026Pooled it
- Efficacy of semilunar ganglion radiofrequency thermal coagulation in moderate and severe trigeminal postherpetic neuralgia and its impact on serum IL-1β and IL-6 levels.European journal of medical research · 2025Trial
- A Novel Machine Learning Signature Incorporating Lipid and Inflammatory Biomarkers to Predict Pulsed Radiofrequency Efficacy in Zoster-Associated Pain.Pain and therapy · 2026Article
- Postherpetic Neuralgia: Mechanisms, Risk Factors, and Stratified Management-A Narrative Review.CNS neuroscience & therapeutics · 2026Review
- Effect of Transcranial Magnetic Stimulation in Patients with Postherpetic Neuralgia and Comorbid Depression: A Randomized Controlled Trial.Pain and therapy · 2026Article
- Effect of transcranial magnetic stimulation on prognosis in patients with postherpetic neuralgia and comorbid depression undergoing interventional neuromodulation therapy: protocol for a randomized double-blind placebo-controlled trial.Frontiers in psychiatry · 2026Article
- Predicting Treatment Response to Pulsed Radiofrequency in Postherpetic Neuralgia Using an Explainable Machine Learning Model.Journal of pain research · 2026Article
- Comparative efficacy and safety of pulsed radiofrequency versus spinal cord stimulation in thoracic herpes zoster pain: a retrospective study.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zoster-associated neuralgia (ZAN) is recognized as a challenging neuralgia that often leads to poor prognosis in patients receiving interventional pain management. Identifying risk factors early can enable clinicians to develop personalized treatment plans; however, research in this area is limited. Methods: We retrospectively screened all patients with ZAN who received interventional therapy in the Pain Department of Soochow University First Affiliated Hospital from January 1, 2022 to August 31, 2023. Data on patient demographics, medical history, neutrophil-to-lymphocyte ratio (NLR), clinical scoring, and treatment methods were collected. Interventional therapy included short-term nerve electrical stimulation (st-NES), pulsed radiofrequency (PRF) and radiofrequency thermocoagulation (RF-TC). Patients were categorized into poor prognosis and control groups based on outcomes 3 months post-discharge. Multivariate logistic regression was used to identify risk factors for poor prognosis. Results: The final analysis included 282 patients. The rate of poor prognosis was 32.6% (92/282). Multivariate logistic regression analysis revealed that age ≥ 65 years (odds ratio, 2.985; 95% confidence interval, 1.449-6.148; Conclusion: Age ≥ 65 years (odds ratio, 2.985; 95% confidence interval, 1.449-6.148;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.